DNA 백신 시장 : 제품 유형, 유형, 최종사용자별 - 세계 기회 분석 및 산업 예측(2021-2030년)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 DNA 백신 시장 규모는 2020년 4억 2,277만 달러에서 예측 기간 중 6.3%의 CAGR로 추이하며, 2030년에는 7억 7,443만 달러 규모로 성장할 것으로 예측됩니다.

DNA 백신 시장의 주요 촉진요인으로는 인간 및 동물에서 암 및 감염증의 유행, 낮은 감염 리스크, 운송의 용이성, 실온에서의 안정성 등의 이점에 의한 DNA 백신 수요의 증가 등을 들 수 있습니다. 또한 항생제에 내성을 가진 병원체의 증가에 의해 장기적인 면역력을 초래하는 DNA 백신과 같은 효과적이며 저비용인 백신 접종의 필요성이 발생하며 DNA 백신 시장의 성장을 한층 더 지원하고 있습니다. 한편, DNA 백신에는 면역원성이 없으므로 시장의 성장을 저해할 가능성이 있습니다. 또한 DNA 백신의 인간에 대한 영향에 관한 지식이 한정되어 있는 것도 시장의 성장을 제한하는 요인이 될 것으로 예상되고 있습니다.

세계의 DNA 백신 시장을 조사했으며, 시장의 정의와 개요, 시장 영향요인 분석, 시장 규모의 추이·예측, 제품 유형·유형·최종사용자·지역/주요 국가 등 각종 부문별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 개요

제3장 시장 개요

• 시장의 정의·범위
• 주요 조사 결과
• Porter의 산업 분석
• 주요 기업의 포지셔닝
• 시장 역학
  • 촉진요인
  • 억제요인
  • 시장 기회
  • 영향 분석
• COVID-19 : 영향 분석
• 인간 DNA 백신

제4장 DNA 백신 시장 : 제품 유형별

• 개요
• Oncept
• West Nile-Innovator
• Apex-IHN
  • 주요 시장 동향·성장요인·기회
  • 시장 규모·예측 : 국가별
  • 시장 분석 : 국가별

제5장 DNA 백신 시장 : 유형별

• 개요
• 치료용 백신
• 예방 백신
  • 시장 규모·예측 : 국가별
  • 시장 분석 : 국가별

제6장 DNA 백신 시장 : 최종사용자별

• 개요
• 수의 클리닉
• 수의 병원
  • 시장 규모·예측 : 국가별
  • 시장 분석 : 국가별

제7장 DNA 백신 시장 : 지역별

• 개요
• 북미
  • 시장 규모·예측 : 제품 유형별
  • 시장 규모·예측 : 유형별
  • 시장 규모·예측 : 최종사용자별

제8장 기업 개요

• BOEHRINGER INGELHEIM GmbH(MERIAL)
• ELI-LILLY(NOVARTIS ANIMAL HEALTH)
• GENEONE LIFE SCIENCE
• GEOVAX LABS, INC.
• INOVIO PHARMACEUTICALS(VGX ANIMAL HEALTH)
• GENEXINE, INC.
• VIATRIS INC.(ROTTAPHARM BIOTECH)
• TAKARA HOLDINGS(TAKARA BIO)
• ZOETIS INC.(FORT DODGE ANIMAL HEALTH)
• ZYDUS CADILA

LIST OF TABLES

• TABLE 01.GLOBAL DNA VACCINES MARKET, BY PRODUCT TYPE, 2020-2030($MILLION)
• TABLE 02.DNA VACCINE MARKET FOR ONCEPT, BY COUNTRY, 2020-2030($MILLION)
• TABLE 03.DNA VACCINE MARKET FOR WEST NILE-INNOVATOR, BY COUNTRY, 2020-2030($MILLION)
• TABLE 04.DNA VACCINE MARKET FOR APEX-IHN, BY COUNTRY, 2020-2030($MILLION)
• TABLE 05.GLOBAL DNA VACCINE MARKET, BY TYPE, 2020-2030($MILLION)
• TABLE 06.DNA VACCINE MARKET FOR THERAPEUTIC VACCINE, BY COUNTRY, 2020-2030($MILLION)
• TABLE 07.DNA VACCINE MARKET FOR PROPHYLACTIC VACCINES, BY COUNTRY, 2020-2030($MILLION)
• TABLE 08.GLOBAL DNA VACCINE MARKET, BY END USER, 2020-2030($MILLION)
• TABLE 09.DNA VACCINE MARKET FOR VETERINARY CLINICS, BY COUNTRY, 2020-2030($MILLION)
• TABLE 10.DNA VACCINE MARKET FOR VETERINARY HOSPITALS, BY COUNTRY, 2020-2030($MILLION)
• TABLE 11.NORTH AMERICA DNA VACCINE MARKET, BY COUNTRY, 2020-2030($MILLION)
• TABLE 12.U.S. DNA VACCINE MARKET, BY PRODUCT TYPE, 2020-2030($MILLION)
• TABLE 13.U.S. DNA VACCINE MARKET, BY TYPE, 2020-2030($MILLION)
• TABLE 14.U.S. DNA VACCINE MARKET, BY END USER, 2020-2030($MILLION)
• TABLE 15.CANADA DNA VACCINE MARKET, BY PRODUCT TYPE, 2020-2030($MILLION)
• TABLE 16.CANADA DNA VACCINE MARKET, BY TYPE, 2020-2030($MILLION)
• TABLE 17.CANADA DNA VACCINE MARKET, BY END USER, 2020-2030($MILLION)
• TABLE 18.NORTH AMERICA DNA VACCINE MARKET, BY PRODUCT TYPE, 2020-2030($MILLION)
• TABLE 19.NORTH AMERICA DNA VACCINE MARKET, BY TYPE, 2020-2030($MILLION)
• TABLE 20.NORTH AMERICA DNA VACCINE MARKET, BY END USER, 2020-2030($MILLION)
• TABLE 21.BOEHRINGER: COMPANY SNAPSHOT
• TABLE 22.BOEHRINGER: OPERATING SEGMENTS
• TABLE 23.BOEHRINGER: PRODUCT PORTFOLIO
• TABLE 24.LILLY:COMPANY SNAPSHOT
• TABLE 25.LILLY: OPERATING SEGMENTS
• TABLE 26.LILLY: PRODUCT PORTFOLIO
• TABLE 27.GENEONE : COMPANY SNAPSHOT
• TABLE 28.LILLY: OPERATING SEGMENTS
• TABLE 29.GENEONE: PRODUCT PORTFOLIO
• TABLE 30.GEOVAX: COMPANY SNAPSHOT
• TABLE 31.GEOVAX: OPERATING SEGMENTS
• TABLE 32.GEOVAX: PRODUCT PORTFOLIO
• TABLE 33.INOVIO: COMPANY SNAPSHOT
• TABLE 34.INOVIO: OPERATING SEGMENTS
• TABLE 35.INOVIO: PRODUCT PORTFOLIO
• TABLE 36.GENEXINE, INC.: COMPANY SNAPSHOT
• TABLE 37.GENEXINE, INC: OPERATING SEGMENTS
• TABLE 38.GENEXINE, INC: PRODUCT PORTFOLIO
• TABLE 39.VIATRIS: COMPANY SNAPSHOT
• TABLE 40.VIATRIS : OPERATING SEGMENTS
• TABLE 41.VIATRIS: PRODUCT PORTFOLIO
• TABLE 42.TAKARA HOLDINGS: COMPANY SNAPSHOT
• TABLE 43.TAKARA BIO: OPERATING SEGMENTS
• TABLE 44.TAKARA HOLDINGS: PRODUCT PORTFOLIO
• TABLE 45.ZOETIS: COMPANY SNAPSHOT
• TABLE 46.ZOETIS: OPERATING SEGMENTS
• TABLE 47.ZOETIS: PRODUCT PORTFOLIO
• TABLE 48.CADILA: COMPANY SNAPSHOT
• TABLE 49.CADILA: OPERATING SEGMENTS
• TABLE 50.CADILA: PRODUCT PORTFOLIO

LIST OF FIGURES

• FIGURE 01.DNA VACCINE MARKET SEGMENTATION
• FIGURE 02.TOP INVESTMENT POCKETS
• FIGURE 03.LOW BARGAINING POWER OF SUPPLIERS
• FIGURE 04.MODERATE BARGAINING POWER OF BUYERS
• FIGURE 05.MODERATE THREAT OF SUBSTITUTES
• FIGURE 06.MODERATE THREAT OF NEW ENTRANTS
• FIGURE 07.HIGH INTENSITY OF RIVALRY
• FIGURE 08.TOP PLAYER POSITIONING, 2020
• FIGURE 09.IMPACT ANALYSIS
• FIGURE 10.HUMAN DNA VACCINE MARKET
• FIGURE 11.COMPARATIVE ANALYSIS OF DNA VACCINE MARKET FOR ONCEPT, BY COUNTRY, 2020 & 2030 (%)
• FIGURE 12.COMPARATIVE ANALYSIS OF DNA VACCINE MARKET FOR WEST NILE-INNOVATOR, BY COUNTRY, 2020 & 2030 (%)
• FIGURE 13.COMPARATIVE ANALYSIS OF DNA VACCINE MARKET FOR APEX-IHN, BY COUNTRY, 2020 & 2030 (%)
• FIGURE 14.COMPARATIVE ANALYSIS DNA VACCINE MARKET FOR THERAPEUTIC VACCINES, BY COUNTRY, 2020 & 2030 (%)
• FIGURE 15.COMPARATIVE ANALYSIS OF DNA VACCINE MARKET FOR PROPHYLACTIC VACCINES, BY COUNTRY, 2020 & 2030 (%)
• FIGURE 16.COMPARATIVE ANALYSIS OF DNA VACCINE MARKET FOR VETERINARY CLINICS, BY COUNTRY, 2020 & 2030 ($MILLION)
• FIGURE 17.COMPARATIVE ANALYSIS OF DNA VACCINE MARKET FOR VETERINARY HOSPITALS, BY COUNTRY, 2020 & 2030 (%)
• FIGURE 18.BOEHRINGER: REVENUE, 2018-2020 ($MILLION)
• FIGURE 19.BOEHRINGER: REVENUE SHARE BY SEGMENT, 2020 (%)
• FIGURE 20.BOEHRINGER: REVENUE SHARE BY REGION, 2020 (%)
• FIGURE 21.LILLY: NET SALES 2018- 2020 ($MILLION)
• FIGURE 22.LILLY: REVENUE SHARE BY REGION, 2020 (%)
• FIGURE 23.GEOVAX: NET SALES 2018- 2020 ($MILLION)
• FIGURE 24.INOVIO: NET SALES, 2018-2020, ($MILLION)
• FIGURE 25.VIATRIS: NET SALES, 2018-2020 ($MILLION)
• FIGURE 26.VIATRIS: REVENUE SHARE BY SEGMENT, 2020 (%)
• FIGURE 27.VIATRIS: REVENUE SHARE BY REGION, 2020 (%)
• FIGURE 28.TAKARA HOLDINGS: NET SALES, 2019-2021, ($MILLION)
• FIGURE 29.TAKARA HOLDINGS: REVENUE SHARE BY SEGMENT, 2021 (%)
• FIGURE 30.ZOETIS: NET SALES, 2018-2020 ($MILLION)
• FIGURE 31.ZOETIS: REVENUE SHARE BY PRODUCT, 2020 (%)
• FIGURE 32.ZOETIS: REVENUE SHARE BY REGION, 2020(%)
• FIGURE 33.CADILA: NET SALES, 2019-2021 ($MILLION)
• FIGURE 34.CADILA: REVENUE SHARE BY SEGMENT, 2021 (%)
• FIGURE 35.CADILA: REVENUE SHARE BY REGION, 2021 (%)

The global DNA vaccine market was valued at $422.77 million in 2020 and is projected to reach $774.43 million by 2030 registering a CAGR of 6.3% from 2021 to 2030.

DNA vaccines is a small, circular DNA plasmid that encodes one or more protein antigens under the control of a promoter to produce a specific immune response against disease. DNA vaccines are the third-generation vaccines specifically designed to overcome the unsought properties of conventional vaccines. Increase in vulnerability of the population to infectious diseases and rise in number of antibiotics-resistant pathogens have created the need for effective and low-cost vaccination, which would provide long-lasting immunity.

The main driving factors of the DNA vaccines market include, rise in prevalence of cancer and infectious diseases in humans and animals, increase in demand for DNA vaccines owing to its advantages such as low risk of infection, easy transportation and stability at room temperature. In addition, increase in number of antibiotics resistant pathogens has created the need for effective and low-cost vaccination such as DNA vaccines, which would provide long lasting immunity, further boost growth of the DNA vaccines market.

However, lack of immunogenicity associated with DNA vaccines may hamper the growth of the market. Furthermore, limited knowledge of the effects of DNA vaccines on humans is also expected to limit the growth of the market. In contrast, development of novel vaccines using DNA technology, and high growth potential in untapped emerging economies are some factors that are expected to offer lucrative growth opportunities for players in the DNA vaccines market.

The global DNA vaccines market is segmented on the basis of product type, type, end user, and region to provide a detailed assessment of the market. By product type, it is segmented into Oncept, West Nile-Innovator, and Apex-IHN. By type, the market is segmented into therapeutic vaccines and prophylactic vaccines. Based on end user, it is categorized into veterinary clinics, veterinary hospitals. Region wise, the market is analyzed only across North America as DNA vaccine products have not been approved in the other regions.

KEY BENEFITS FOR STAKEHOLDERS

• The study provides an in-depth analysis of the DNA vaccines market along with the current trends and future estimations to explain the imminent investment pockets.
• A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
• Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
• Extensive analysis of the key segments of the industry helps to understand the application and products of DNA vaccines used across the globe.
• Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Product Type

• Oncept
• West Nile-Innovator
• Apex-IHN

By Type

• Therapeutic Vaccines
• Prophylactic Vaccines

By End User

• Veterinary Clinics
• Veterinary Hospitals

By Region

• North America
• U.S.
• Canada

LIST OF KEY PLAYERS PROFILED IN THE REPORT

• BOEHRINGER INGELHEIM GmbH (Merial)
• ELI-LILLY (Novartis Animal Health)
• GeneOne Life Science
• GEOVAX LABS, INC
• Inovio Pharmaceuticals (VGX Animal Health)
• Genexine, Inc.
• VIATRIS INC. (Rottapharm Biotech)
• Takara Holdings (Takara Bio)
• ZOETIS INC. (Fort dodge Animal Health)
• Zydus Cadila

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

• 1.1.Report description
• 1.2.Key benefits for stakeholders
• 1.3.Key market segments
  • 1.3.1.List of key players profiled in the report
• 1.4.Research methodology
  • 1.4.1.Secondary research
  • 1.4.2.Primary research
  • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

• 2.1.Key findings of the study
• 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

• 3.1.Market definition and scope
• 3.2.Key findings
  • 3.2.1.Top investment pockets
  • 3.2.2.Top winning strategies
• 3.3.Porter's five force analysis
• 3.4.Top player positioning, 2020
• 3.5.Market dynamics
  • 3.5.1.Drivers
    • 3.5.1.1.Rise in prevalence of cancer and infectious diseases in humans and animals
    • 3.5.1.2.Increase in demand for DNA vaccines
    • 3.5.1.3.Growth in number of antibiotic resistant pathogens
  • 3.5.2.Restraints
    • 3.5.2.1.Lack of immunogenicity associated with DNA vaccines
    • 3.5.2.2.Limited knowledge about the effects of DNA vaccines on humans
  • 3.5.3.Opportunities
    • 3.5.3.1.Development of novel vaccines using DNA technology
    • 3.5.3.2.High growth potential in untapped emerging economies
  • 3.5.4.Impact analysis
• 3.6.COVID-19 Impact analysis on the DNA vaccine market
• 3.7.Human DNA vaccine

CHAPTER 4:DNA VACCINE MARKET, BY PRODUCT TYPE

• 4.1.Overview
  • 4.1.1.Market size and forecast
• 4.2.Oncept
  • 4.2.1.Key market trends, growth factors, and opportunities
  • 4.2.2.Market size and forecast, by country
  • 4.2.3.Market analysis, by country
• 4.3.West Nile-Innovator
  • 4.3.1.Key market trends, growth factors, and opportunities
  • 4.3.2.Market size and forecast, by country
  • 4.3.3.Market analysis, by country
• 4.4.Apex-IHN
  • 4.4.1.Key market trends, growth factors, and opportunities
  • 4.4.2.Market size and forecast, by country
  • 4.4.3.Market analysis, by country

CHAPTER 5:DNA VACCINE MARKET, BY TYPE

• 5.1.Overview
  • 5.1.1.Market size and forecast
• 5.2.Therapeutic Vaccines
  • 5.2.1.Market size and forecast, by country
  • 5.2.2.Market analysis, by country
• 5.3.Prophylactic Vaccines
  • 5.3.1.Market size and forecast, by country
  • 5.3.2.Market analysis, by country

CHAPTER 6:DNA VACCINE MARKET, BY END USER

• 6.1.Overview
  • 6.1.1.Market size and forecast
• 6.2.Veterinary Clinics
  • 6.2.1.Market size and forecast, by country
  • 6.2.2.Market analysis, by country
• 6.3.Veterinary Hospitals
  • 6.3.1.Market size and forecast, by country
  • 6.3.2.Market analysis, by country

CHAPTER 7:DNA VACCINE MARKET, BY REGION

• 7.1.Overview
• 7.2.North America
  • 7.2.1.Key market trends, growth factors, and opportunities
  • 7.2.2.Market size and forecast, by country
    • 7.2.2.1.U.S.
    • 7.2.2.1.1.U.S. DNA vaccine market, by product type
    • 7.2.2.1.2.U.S. DNA vaccine market, by type
    • 7.2.2.1.3.U.S. DNA vaccine market, by end user
    • 7.2.2.2.Canada
    • 7.2.2.2.1.Canada DNA vaccine market, by product type
    • 7.2.2.2.2.Canada DNA vaccine market, by type
    • 7.2.2.2.3.Canada DNA vaccine market, by end user
  • 7.2.3.North America market size and forecast, by product type
  • 7.2.4.North America market size and forecast, by type
  • 7.2.5.North America market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

• 8.1.BOEHRINGER INGELHEIM GmbH (MERIAL)
  • 8.1.1.Company overview
  • 8.1.2.Operating business segments
  • 8.1.3.Product portfolio
  • 8.1.4.Business performance
• 8.2.ELI-LILLY (NOVARTIS ANIMAL HEALTH)
  • 8.2.1.Company overview
  • 8.2.2.Company snapshot
  • 8.2.3.Operating business segments
  • 8.2.4.Product portfolio
  • 8.2.5.Business performance
• 8.3.GENEONE LIFE SCIENCE
  • 8.3.1.Company overview
  • 8.3.2.Company snapshot
  • 8.3.3.Operating business segments
  • 8.3.4.Product portfolio
• 8.4.GEOVAX LABS, INC.
  • 8.4.1.Company overview
  • 8.4.2.Company snapshot
  • 8.4.3.Operating business segments
  • 8.4.4.Product portfolio
  • 8.4.5.Business performance
• 8.5.INOVIO PHARMACEUTICALS (VGX ANIMAL HEALTH)
  • 8.5.1.Company overview
  • 8.5.2.Company snapshot
  • 8.5.3.Operating business segments
  • 8.5.4.Product portfolio
  • 8.5.5.Business performance
• 8.6.GENEXINE, INC.
  • 8.6.1.Company overview
  • 8.6.2.Company snapshot
  • 8.6.3.Operating business segments
  • 8.6.4.Product portfolio
• 8.7.VIATRIS INC. (ROTTAPHARM BIOTECH)
  • 8.7.1.Company overview
  • 8.7.2.Company snapshot
  • 8.7.3.Operating business segments
  • 8.7.4.Product Portfolio
  • 8.7.5.Business performance
• 8.8.TAKARA HOLDINGS (TAKARA BIO)
  • 8.8.1.Company overview
  • 8.8.2.Company snapshot
  • 8.8.3.Operating business segments
  • 8.8.4.Product portfolio
  • 8.8.5.Business performance
• 8.9.ZOETIS INC. (FORT DODGE ANIMAL HEALTH)
  • 8.9.1.Company overview
  • 8.9.2.Company snapshot
  • 8.9.3.Operating business segments
  • 8.9.4.Product portfolio
  • 8.9.5.Business performance
• 8.10.ZYDUS CADILA
  • 8.10.1.Company overview
  • 8.10.2.Company snapshot
  • 8.10.3.Operating business segments
  • 8.10.4.Product portfolio
  • 8.10.5.Business performance
  • 8.10.6.Key strategic moves and developments